Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Therapeutic Implications of GIPC1 Silencing in Cancer

Figure 1

The effects of GIPC1 silencing on cell proliferation and apoptosis in MDA-MB231 human breast cancer cells.

A. Assessment of cell viability (blue) and caspase 3/7 activity (pink) at 0, 24, 48, and 72 hours. Solid lines with blue boxes (non-transduced) and blue diamonds (non-target) and dashed line with blue triangles (GIPC1 KD) indicate cell viability. Pink denotes caspase 3/7 activity. B. Normalized caspase 3/7 activity. Total caspase 3/7 activity was normalized to cell viability and assessed at 0, 24, 48, and 72 hours. Normalization indicates a 2.1 fold increase in caspase 3/7 activity in GIPC1 KD cells compared to non-target cells at 72 hours. C. Tunnel assay. DNA fragmentation was assessed as % positive control. GIPC1 KD correlates with an 11.24 fold increase in apoptosis (GIPC1/Non-target; P<0.05). D. Evaluation of cell proliferation after VEGF (10 ng/ml) induction. Proliferation was evaluated at 0, 24, 48, and 72 hours. Days 1, 2, and 3 were normalized to day 0. Solid lines with blue boxes (non-transduced) and blue diamonds (non-target) and dashed line with blue triangles (GIPC1 KD) indicate cell proliferation in starvation media. Pink denotes VEGF induction. D. Evaluation of cleaved PARP1. PARP1, cleaved PARP1, GIPC1, and GAPDH expression was assessed by western blot in MDA-MB231 human breast cancer cells. Data are presented as means ± SEM. Asterisks indicate statistical significance (P≤0.05) between non-target and GIPC1 KD conditions.

Figure 1

doi: https://doi.org/10.1371/journal.pone.0015581.g001